HOME > 상세정보

상세정보

Resistance to proteasome inhibitors in cancer [electronic resource] : molecular mechanisms and strategies to overcome resistance

Resistance to proteasome inhibitors in cancer [electronic resource] : molecular mechanisms and strategies to overcome resistance

자료유형
E-Book(소장)
개인저자
Dou, Q. Ping.
서명 / 저자사항
Resistance to proteasome inhibitors in cancer [electronic resource] : molecular mechanisms and strategies to overcome resistance / edited by Q. Ping Dou.
발행사항
Cham :   Springer International Publishing :   Imprint: Springer,   2014.  
형태사항
1 online resource (xi, 390 p.) : ill. (chiefly col.).
총서사항
Resistance to Targeted Anti-Cancer Therapeutics,2196-5501
ISBN
9783319067520
요약
The book explores cutting-edge strategies to overcome proteasome inhibitor resistance, including the second generation 20S proteasome inhibitors, novel combinational therapies, and new targets in the ubiquitin-proteasome pathway (e.g., ubiquitin E3 ligases, deubiquitinases, 19S proteasomal ATPases, histone deacetylases, oxidative stress and proteotoxic stress pathways and pharmacogenomic signature profiling) in resistant cancer cells. The mechanisms of action and resistance of proteasome inhibitors, such as bortezomib and carfilzomib in human cancers, including multiple myeloma, mantle cell lymphoma, acute leukemia, and solid tumors are explored in depth in this volume. This timely volume unveils the most current discoveries of the mechanisms behind proteasome inhibitor resistance, which will help illuminate the future of cancer therapies.
일반주기
Title from e-Book title page.  
내용주기
Proteasome inhibitors and lessons learned from their mechanisms of action and resistance in human cancer -- Resistance to proteasome inhibitors in multiple myeloma -- Overcoming bortezomib resistance: a review on the second generation proteasome inhibitor carfilzomib in the treatment of multiple myeloma -- Proteasome inhibitors in the treatment of multiple myeloma and amyloidosis -- Profiling bortezomib resistance in multiple myeloma: implications in personalized pharmacotherapy -- Targeting mantle cell lymphoma with a strategy of combined proteasome and histone deacetylase inhibition -- Pre-clinical studies on the molecular basis of bortezomib resistance and modalities to overcome resistance in hematological malignancies -- Overcoming inherent resistance to proteasome inhibitors in head and neck cancer: Challenges and new approaches -- Targeting the proteasome pathway for the treatment of solid tumors -- Oxidative stress and the proteasome: mechanism and the therapeutic relevance -- Proteotoxic stress and proteasome inhibitor efficacy and resistance -- Proteasome inhibitors versus E3 ligase inhibitors for cancer therapy -- Novel ubiquitin E3 ligases as targets for cancer therapy: Focus on breast cancer associated gene 2 (BCA2) -- The 26S proteasomal ATPases: structure, function, regulation and potential for cancer therapies -- Deubiquitinating enzymes as novel targets for cancer therapies.
서지주기
Includes bibliographical references and index.
이용가능한 다른형태자료
Issued also as a book.  
일반주제명
Cancer --Chemotherapy.
바로가기
URL
000 00000nam u2200205 a 4500
001 000046047115
005 20200923145618
006 m d
007 cr
008 200916s2014 sz a ob 001 0 eng d
020 ▼a 9783319067520
040 ▼a 211009 ▼c 211009 ▼d 211009
082 0 4 ▼a 616.994061 ▼2 23
084 ▼a 616.994061 ▼2 DDCK
090 ▼a 616.994061
245 0 0 ▼a Resistance to proteasome inhibitors in cancer ▼h [electronic resource] : ▼b molecular mechanisms and strategies to overcome resistance / ▼c edited by Q. Ping Dou.
260 ▼a Cham : ▼b Springer International Publishing : ▼b Imprint: Springer, ▼c 2014.
300 ▼a 1 online resource (xi, 390 p.) : ▼b ill. (chiefly col.).
490 1 ▼a Resistance to Targeted Anti-Cancer Therapeutics, ▼x 2196-5501
500 ▼a Title from e-Book title page.
504 ▼a Includes bibliographical references and index.
505 0 ▼a Proteasome inhibitors and lessons learned from their mechanisms of action and resistance in human cancer -- Resistance to proteasome inhibitors in multiple myeloma -- Overcoming bortezomib resistance: a review on the second generation proteasome inhibitor carfilzomib in the treatment of multiple myeloma -- Proteasome inhibitors in the treatment of multiple myeloma and amyloidosis -- Profiling bortezomib resistance in multiple myeloma: implications in personalized pharmacotherapy -- Targeting mantle cell lymphoma with a strategy of combined proteasome and histone deacetylase inhibition -- Pre-clinical studies on the molecular basis of bortezomib resistance and modalities to overcome resistance in hematological malignancies -- Overcoming inherent resistance to proteasome inhibitors in head and neck cancer: Challenges and new approaches -- Targeting the proteasome pathway for the treatment of solid tumors -- Oxidative stress and the proteasome: mechanism and the therapeutic relevance -- Proteotoxic stress and proteasome inhibitor efficacy and resistance -- Proteasome inhibitors versus E3 ligase inhibitors for cancer therapy -- Novel ubiquitin E3 ligases as targets for cancer therapy: Focus on breast cancer associated gene 2 (BCA2) -- The 26S proteasomal ATPases: structure, function, regulation and potential for cancer therapies -- Deubiquitinating enzymes as novel targets for cancer therapies.
520 ▼a The book explores cutting-edge strategies to overcome proteasome inhibitor resistance, including the second generation 20S proteasome inhibitors, novel combinational therapies, and new targets in the ubiquitin-proteasome pathway (e.g., ubiquitin E3 ligases, deubiquitinases, 19S proteasomal ATPases, histone deacetylases, oxidative stress and proteotoxic stress pathways and pharmacogenomic signature profiling) in resistant cancer cells. The mechanisms of action and resistance of proteasome inhibitors, such as bortezomib and carfilzomib in human cancers, including multiple myeloma, mantle cell lymphoma, acute leukemia, and solid tumors are explored in depth in this volume. This timely volume unveils the most current discoveries of the mechanisms behind proteasome inhibitor resistance, which will help illuminate the future of cancer therapies.
530 ▼a Issued also as a book.
538 ▼a Mode of access: World Wide Web.
650 0 ▼a Cancer ▼x Chemotherapy.
700 1 ▼a Dou, Q. Ping.
830 0 ▼a Resistance to Targeted Anti-Cancer Therapeutics.
856 4 0 ▼u https://oca.korea.ac.kr/link.n2s?url=http://dx.doi.org/10.1007/978-3-319-06752-0
945 ▼a KLPA
991 ▼a E-Book(소장)

소장정보

No. 소장처 청구기호 등록번호 도서상태 반납예정일 예약 서비스
No. 1 소장처 중앙도서관/e-Book 컬렉션/ 청구기호 CR 616.994061 등록번호 E14033174 도서상태 대출불가(열람가능) 반납예정일 예약 서비스 M

관련분야 신착자료

WHO Classification of Tumours Editorial Board (2021)
대한가정의학회. 비만대사증후군연구회 (2021)
Hargadon, Kristian M (2021)
Stein, Ulrike S (2021)
Santiago-Cardona, Pedro G (2021)